dc.contributor.author | Alejos, Belén | |
dc.contributor.author | Díez, Cristina | |
dc.contributor.author | Galindo, María J | |
dc.contributor.author | López, Juan C | |
dc.contributor.author | Moreno-García, Estela | |
dc.contributor.author | Estrada, Vicente | |
dc.contributor.author | Poveda, Eva | |
dc.contributor.author | Omar, Mohamed | |
dc.contributor.author | Jarrin-Vera, Inmaculada | |
dc.contributor.author | Berenguer, Juan | |
dc.date.accessioned | 2023-04-14T13:12:44Z | |
dc.date.available | 2023-04-14T13:12:44Z | |
dc.date.issued | 2022-08 | |
dc.identifier.citation | Antivir Ther. 2022 Aug;27(4):13596535221112729. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15815 | |
dc.description.abstract | Background: We monitored the quality of care for newly diagnosed people with HIV (PWH) in Spain, including linkage to care within 1 month of HIV diagnosis (LC-1Mo) and viral suppression within 3 months of HIV diagnosis (VS-3Mo). Methods: Longitudinal study based on The Cohort of the Spanish AIDS Research Network (CoRIS). We used logistic regression stratified by year of HIV diagnosis (2004-2013 and 2014-2019) to assess differences by sex, country of origin, HIV risk group, age, prior AIDS, HIV Viral Load, and CD4 cell count. Results: The final analysis included 13,632 PWH: males 85%, men having sex with men (MSM) 61%, median age 35 years. LC-1Mo increased from 42% (95% CI, 38%-46%) in 2004 to 80% (95% CI, 77%-83%) in 2019 (P < 0.001). Median CD4+ cell counts at ART initiation increased from <250/mm3 in 2004-2005 to >350/mm3 since 2012 (P < 0.001). The percentage of initial regimens based on integrase strand transfer inhibitors (INSTI) increased from 3% in 2004 to >70% from 2016 onwards (P < 0.001). VS-3Mo increased from 6% (95% CI, 4%-8%) in 2004 to 45% (95% CI, 41%-49%) in 2019 (P < 0.001). Worst results for LC-1Mo were found among PWH acquiring HIV by injection drug use and those born in Latin American Countries across all the study period. Conclusion: Care indicators have improved among newly diagnosed PWH in Spain over the last 15 years. Removal of CD4 cell counts limitations, and probably the increasing use of INSTI-based regimens was decisive for the progress made. | es_ES |
dc.description.sponsorship | The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD16/0025/0017 and RD16/0002/0006) as part of the Plan Nacional I+D+i and cofinanced by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | SAGE Publishing | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Sexual and Gender Minorities | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | CD4 Lymphocyte Count | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Homosexuality, Male | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Longitudinal Studies | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Spain | es_ES |
dc.subject.mesh | Viral Load | es_ES |
dc.title | Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019) | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial 4.0 Internacional | * |
dc.identifier.pubmedID | 35802475 | es_ES |
dc.format.volume | 27 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 13596535221112729 | es_ES |
dc.identifier.doi | 10.1177/13596535221112729 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2040-2058 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1177/13596535221112729 | es_ES |
dc.identifier.journal | Antiviral therapy | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0017/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0002/0006 | es_ES |